TABLE 2.
PK data for longer-acting partner drugs, AQ, DEAQ, and LR, in children
| PK parameter | AQa | DEAQb | LRb |
|---|---|---|---|
| Cmax (ng/ml) | 5.2 | 235 (219-266) | 6,757 (6,118-9,291) |
| AUC0-120 (ng·h/ml)c | NAd | 11,242 (10,580-12,367) | 194,740 (173,935-288,471) |
| AUC0-8 (ng·h/ml)c | 28.9 | NA | NA |
| AUC0-∞ (ng·h/ml)c | 39.3 | 14,770 (13,914-16,226) | 210,040 (188,859-307,217) |
| t1/2 (h)e | 3.3 | 60.0 (56.9-64.6) | 32.7 |
a
Data were estimated by using pooled data from all subjects.
b
Data were estimated by using pooled data from individual subjects. Data represent the geometric means (90% CIs).
c
AUC estimated surrounding the last dose administered.
d
NA, not applicable.
e
t1/2, elimination half-life.